Results 51 to 60 of about 231,349 (305)

Translational target for checkpoint inhibitors [PDF]

Nature Reviews Immunology, 2018
Eukaryotic translation initiation complex eIF4F is identified as an upstream regulator of PD-L1 expression and is therefore a promising target for immunotherapy.
openaire   +2 more sources

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

BMC Pulmonary Medicine, 2021
Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM)
Steven G. Gray
doaj   +1 more source

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Vaccines, 2023
Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang, Changwei Hu, Xiaoxiao Xie, Linzhi Qi, Chuanzhou Li, Shangze Li   +5 more
doaj   +1 more source

The role of immune checkpoint inhibitors in prostate cancer

, 2018
Introduction Prostate cancer (PC) is the most commonly diagnosed malignant tumour and the third cause of cancer deaths among men in Europe. The treatment of early-stage PC is very effective and in many cases allows achievement of a complete cure, whereas
Marek Hus, Katarzyna Chyl-Surdacka, Gabriel Surdacki, Surdacki, G., Szudy-Szczyrek, A., Chyl-Surdacka, K., Gorący, A., Hus, M., Aneta Gorący, Aneta Szudy-Szczyrek   +9 more
core   +1 more source

Management of the Cardiovascular Adverse Effects of Immune Checkpoint Inhibitors

, 2023
With the rising use of immune checkpoint inhibitors in oncologic treatment, many so called immune related adverse events have been described. The guidelines regarding management of hepatitis, gastritis and dermatitis have been well discussed in ...
Elsaygh, Hassan Nabil
core  

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2023
The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang, DONG Shuai, LI Menglong, LIANG Rui   +3 more
doaj   +1 more source

Tracking the tail

Journal for ImmunoTherapy of Cancer, 2020
Immune-checkpoint inhibitors have deeply changed the therapeutic landscape of advanced non-small cell lung cancer without actionable genomic alterations. Immune-checkpoint inhibitors have become standard front-line therapy, especially among patients with
Alex Friedlaender, Alfredo Addeo, Stephen V Liu   +2 more
doaj   +1 more source

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

Frontiers in Oncology, 2022
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera, Maria E. Suarez-Almazor   +1 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

Kidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy, Sandra M. Herrmann, Meghan E. Sise   +2 more
doaj   +1 more source

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Ophthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source